Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
Tweet Send to a FriendGet Alerts ALXN Hot Sheet
Price: $102.90 +1.06%
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
10 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade ALXN Now!
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
Analyst, Salveen Richter, said, "Q1/12 EPS is a key event for some, but overshadowed by M&A and binary catalysts for others: We expect Q1/12 earnings to serve as catalysts for Alexion (Nasdaq: ALXN), Dendreon (Nasdaq: DNDN) and potentially Incyte (Nasdaq: INCY) (in-line/beat is anticipated). However, Amylin (Nasdaq: AMLN) and Human Genome (Nasdaq: HGSI) will be buoyed by M&A speculation (rather than EPS), while for Auxilium (Nasdaq: AUXL) and BioMarin (Nasdaq: BMRN) (expect solid top-line Q1) it is all about data. For Savient (Nasdaq: SVNT) and United Therapeutics (Nasdaq: UTHR), company fundamentals will play an important role on top of EPS outlook."
Canaccord rated ALXN, AUXL, BMRN, INCY and UTHR at a 'Buy' rating. DNDN, HGSI, and SVNT at Hold. AMLN at a Sell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Salveen Richter, said, "Q1/12 EPS is a key event for some, but overshadowed by M&A and binary catalysts for others: We expect Q1/12 earnings to serve as catalysts for Alexion (Nasdaq: ALXN), Dendreon (Nasdaq: DNDN) and potentially Incyte (Nasdaq: INCY) (in-line/beat is anticipated). However, Amylin (Nasdaq: AMLN) and Human Genome (Nasdaq: HGSI) will be buoyed by M&A speculation (rather than EPS), while for Auxilium (Nasdaq: AUXL) and BioMarin (Nasdaq: BMRN) (expect solid top-line Q1) it is all about data. For Savient (Nasdaq: SVNT) and United Therapeutics (Nasdaq: UTHR), company fundamentals will play an important role on top of EPS outlook."
Canaccord rated ALXN, AUXL, BMRN, INCY and UTHR at a 'Buy' rating. DNDN, HGSI, and SVNT at Hold. AMLN at a Sell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Jefferies Buyers of Jack In The Box (JACK) on Solid Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
